Stock Yards Bank & Trust Co. Cuts Position in Zoetis Inc. $ZTS

Stock Yards Bank & Trust Co. decreased its position in Zoetis Inc. (NYSE:ZTS) by 13.5% during the 1st quarter, Holdings Channel reports. The fund owned 66,813 shares of the company’s stock after selling 10,409 shares during the quarter. Stock Yards Bank & Trust Co.’s holdings in Zoetis were worth $7,898,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Global Wealth Strategies & Associates acquired a new stake in Zoetis in the fourth quarter valued at $25,000. Prosperity Bancshares Inc purchased a new stake in Zoetis during the 4th quarter worth about $25,000. KERR FINANCIAL PLANNING Corp acquired a new position in shares of Zoetis during the 3rd quarter worth about $31,000. Lodestone Wealth Management LLC acquired a new position in shares of Zoetis during the 4th quarter worth about $30,000. Finally, Elyxium Wealth LLC purchased a new position in shares of Zoetis in the 4th quarter valued at about $32,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Key Stories Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: One recent note suggested Zoetis’ index shift could reinforce its competitive moat in companion-animal health, which supports the long-term investment case. Zoetis (ZTS) Index Shift: A Harbinger for Its Competitive Moat in Companion-Animal Health?
• Neutral Sentiment: Barclays cut its price target on Zoetis to $85 from $136 and kept an equal-weight rating, signaling a more cautious valuation view but not a bearish downgrade. Barclays price target cut on Zoetis
• Neutral Sentiment: TD Cowen lowered its target to $104 from $150 while maintaining a buy rating, reflecting softer near-term expectations while still seeing upside from current levels. TD Cowen price target cut on Zoetis
• Neutral Sentiment: Multiple firms reminded investors about the July 27 deadline to join the Zoetis securities class action, keeping legal uncertainty in focus for shareholders. Zoetis Inc. (ZTS) Investors: July 27, 2026, Filing Deadline in Securities Fraud Class Action
• Neutral Sentiment: Analyst commentary also highlighted that stabilization in Zoetis products may still be several quarters away, which adds to the view that fundamentals could remain challenged in the near term. This analyst thinks stabilization for Zoetis’ products could be several quarters away
• Negative Sentiment: The series of class-action notices may raise investor concern about alleged misstatements tied to product adoption, adding a legal overhang to the shares. ZOETIS DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL

Insider Transactions at Zoetis

In related news, Director Paul Bisaro purchased 2,000 shares of the stock in a transaction that occurred on Wednesday, May 13th. The shares were purchased at an average price of $75.88 per share, with a total value of $151,760.00. Following the completion of the acquisition, the director directly owned 27,862 shares in the company, valued at $2,114,168.56. This represents a 7.73% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Michael B. Mccallister purchased 3,000 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was bought at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the transaction, the director directly owned 24,524 shares in the company, valued at $1,906,986.24. This trade represents a 13.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders acquired 11,650 shares of company stock worth $886,384. Company insiders own 0.22% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS opened at $72.48 on Thursday. The company’s 50 day simple moving average is $85.77 and its 200-day simple moving average is $109.95. The firm has a market cap of $30.39 billion, a PE ratio of 12.02, a price-to-earnings-growth ratio of 1.12 and a beta of 0.75. Zoetis Inc. has a 12-month low of $71.47 and a 12-month high of $161.77. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. During the same quarter last year, the company earned $1.48 EPS. The firm’s revenue for the quarter was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, equities analysts predict that Zoetis Inc. will post 6.87 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio is presently 35.16%.

Analysts Set New Price Targets

ZTS has been the subject of several recent analyst reports. Wall Street Zen downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Argus reaffirmed a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Stifel Nicolaus cut their price target on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a research note on Friday, June 26th. UBS Group reduced their price target on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research report on Friday, May 8th. Finally, Barclays decreased their price objective on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research note on Wednesday. Seven investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $126.92.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.